HUE057653T2 - Kis aktív choroidális neurovaszkularizáció lézióval jellemzett idõskori makuladegeneráció kezelése - Google Patents

Kis aktív choroidális neurovaszkularizáció lézióval jellemzett idõskori makuladegeneráció kezelése

Info

Publication number
HUE057653T2
HUE057653T2 HUE15819965A HUE15819965A HUE057653T2 HU E057653 T2 HUE057653 T2 HU E057653T2 HU E15819965 A HUE15819965 A HU E15819965A HU E15819965 A HUE15819965 A HU E15819965A HU E057653 T2 HUE057653 T2 HU E057653T2
Authority
HU
Hungary
Prior art keywords
treatment
macular degeneration
related macular
choroidal neovascularization
age related
Prior art date
Application number
HUE15819965A
Other languages
English (en)
Hungarian (hu)
Inventor
Oliver Zeitz
Olaf Sowade
Haiyan Wu
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55069121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE057653(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/CN2014/093548 external-priority patent/WO2016090590A1/en
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of HUE057653T2 publication Critical patent/HUE057653T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HUE15819965A 2014-12-11 2015-12-10 Kis aktív choroidális neurovaszkularizáció lézióval jellemzett idõskori makuladegeneráció kezelése HUE057653T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2014/093548 WO2016090590A1 (en) 2014-12-11 2014-12-11 Treatment of age related macular degeneration with a small active choroidalneovascularizationlesion
CN2015089251 2015-09-09

Publications (1)

Publication Number Publication Date
HUE057653T2 true HUE057653T2 (hu) 2022-05-28

Family

ID=55069121

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15819965A HUE057653T2 (hu) 2014-12-11 2015-12-10 Kis aktív choroidális neurovaszkularizáció lézióval jellemzett idõskori makuladegeneráció kezelése

Country Status (16)

Country Link
US (2) US20170326106A1 (https=)
EP (2) EP3985023A1 (https=)
JP (3) JP7320919B2 (https=)
CN (3) CN114306575A (https=)
AU (4) AU2015360496B2 (https=)
CA (1) CA2970315C (https=)
DK (1) DK3230316T3 (https=)
ES (1) ES2907148T3 (https=)
HR (1) HRP20220066T1 (https=)
HU (1) HUE057653T2 (https=)
LT (1) LT3230316T (https=)
PL (1) PL3230316T3 (https=)
PT (1) PT3230316T (https=)
RS (1) RS62827B1 (https=)
SI (1) SI3230316T1 (https=)
WO (1) WO2016094673A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN114306575A (zh) 2014-12-11 2022-04-12 拜耳医药保健有限责任公司 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
US10525035B2 (en) * 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
SG11202006712XA (en) * 2018-02-06 2020-08-28 Hoffmann La Roche Treatment of ophthalmologic diseases
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
MY195550A (en) 2018-10-29 2023-01-31 Hoffmann La Roche Antibody Formulation
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US11944663B2 (en) * 2020-06-18 2024-04-02 Chengdu Kanghong Biotechnologies Co. Ltd. Method for treating angiogenic eye disorders using VEGF antagonists
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
JP2025036369A (ja) * 2023-08-31 2025-03-14 国立大学法人京都大学 光感受性物質含有リポタンパク質、光線力学的療法用製剤、薬物デリバリー方法及び後眼部新生血管閉塞方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2177950C2 (ru) 1996-10-25 2002-01-10 Нексстар Фармасьютикалз, Инк. Комплексы нуклеиновых кислот - лигандов сосудистого эндотелиального фактора роста (vegf)
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
CN101433715B (zh) 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
CA2437563C (en) * 2001-02-06 2010-03-23 Qlt Inc. Photodynamic therapy of occult age-related macular degeneration
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
KR20190049934A (ko) * 2011-01-13 2019-05-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
CN114306575A (zh) 2014-12-11 2022-04-12 拜耳医药保健有限责任公司 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗

Also Published As

Publication number Publication date
RS62827B1 (sr) 2022-02-28
AU2015360496A1 (en) 2017-05-25
AU2021245214A1 (en) 2021-11-04
DK3230316T3 (da) 2022-03-28
LT3230316T (lt) 2022-02-10
JP2017537117A (ja) 2017-12-14
JP7320919B2 (ja) 2023-08-04
US20190381008A1 (en) 2019-12-19
JP2022183183A (ja) 2022-12-08
PT3230316T (pt) 2022-02-24
AU2021107575A4 (en) 2022-01-06
AU2021245214B2 (en) 2024-05-02
HRP20220066T1 (hr) 2022-04-15
EP3230316A1 (en) 2017-10-18
CN114306575A (zh) 2022-04-12
EP3985023A1 (en) 2022-04-20
WO2016094673A1 (en) 2016-06-16
SI3230316T1 (sl) 2022-05-31
CN112826934A (zh) 2021-05-25
JP2021004262A (ja) 2021-01-14
CA2970315A1 (en) 2016-06-16
CN106999511A (zh) 2017-08-01
CA2970315C (en) 2023-08-22
ES2907148T3 (es) 2022-04-22
AU2024205237A1 (en) 2024-08-22
AU2015360496B2 (en) 2021-09-30
US20170326106A1 (en) 2017-11-16
PL3230316T3 (pl) 2022-05-02
EP3230316B1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
LT3230316T (lt) Gydymas su amžiumi susijusios geltonosios dėmės degeneracijos su mažu aktyvios choroidinės neovaskuliarizacijos pažeidimu
IL265497B (en) Methods for treating eye diseases
IL252159A0 (en) Methods and formulations for the treatment of diseases of the blood vessels of the eye
IL253244B1 (en) Methods for treating retinal diseases
GB201403260D0 (en) Treatment of retinal degeneration using gene therapy
HUE041940T2 (hu) MRNS-terápia szembetegségek kezelésére
IL246791A0 (en) Compositions and methods for treating eye diseases
PT3658140T (pt) Combinações de aprocitentan com outros ingredientes ativos para o tratamento de hipertensão resistente
EP3122782A4 (en) Compositions and methods for treatment of diabetic macular edema
PL2953596T3 (pl) Technika fotodysrupcyjnej, wieloimpulsowej obróbki materiału
IL239736A0 (en) New pitfalls in the treatment of macular degeneration
ZA201704793B (en) Treatment of retinal degeneration using progenitor cells
SG11201607996SA (en) Effect of lipophilic nutrients on diabetic eye diseases
EP3089748A4 (en) Treating ocular neovascularization
SG11201608257RA (en) A device for a medical treatment of a sclera
IL247116B (en) Compositions and methods for treating and preventing macular degeneration
HUE055940T2 (hu) Lencsék intrastromális szaruhártya-beültetéshez
EP3213762A4 (en) Novel treatment of cornea using laminin
GB201412578D0 (en) Treatment of neurological diseases
PL3233174T3 (pl) Wewnątrzgałkowe dostarczanie bioaktywnych cząsteczek za pomocą jontoforezy
IL261891A (en) Active retinal implant
IL252394A0 (en) Methods for preventing, reducing or treating macular degeneration
HK1230941A1 (en) Treating ocular neovascularization
GB201413330D0 (en) Agricultural treatment
GB201406602D0 (en) Biocompatible crotch stiffener